New Agents and Treatments in Metastatic Prostate Cancer

Nasir Chaudry, MD, Allegheny Health Network, discusses what some of the most impactful data has been in the prostate cancer space in recent years, highlighting the many new agents that have come into play.

Some recent approvals from the FDA for patients with metastatic prostate cancer include the combination of niraparib (Zejula) and abiraterone acetate tablets (Akeega) with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), as detected by an FDA-approved test in August 2023, the combination of talazoparib (Talzenna) plus enzalutamide (Xtandi) for the treatment of patients with HRR gene–mutated mCRPC in June 2023, olaparib (Lynparza) in combination with abiraterone and prednisone or prednisolone for adult patients with mCRPC in May 2023, and more.

Transcription:

0:10 | In terms of the data, a big part of it is the advancing treatments that are coming in regards to metastatic disease. I can almost say over the last like, 15-17 years, [we have] only see a new agent come out every few years that is able to extend life expectancies by 6 to 12 months. It used to be that as soon as a cancer became castrate resistant, it is a fairly poor prognosis, but we're starting to see and are able to extend someone's life beyond that point of time.

0:49 | A big thing that's coming out with prostate cancer is whenever you're seeing metastatic disease, in the past it used to be automatic hormonal therapy, and that used to be the mainstay of your therapy. What we're seeing now is potentially doing prostatectomy on patients who have basically oligometastatic disease with often less than 5 sites of metastasis is basically showing survival benefits. Basically, just additional therapies, even in regards to radiation treatments, can often extend people's life and it's showing meaningful benefits, not always curative, but [it is] definitely extending lives.